Levy M L, Cummings J L, Fairbanks L A, Sultzer D L, Small G W
Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine 90095-1769, USA.
Biol Psychiatry. 1999 Feb 15;45(4):422-5. doi: 10.1016/s0006-3223(98)00041-9.
The apolipoprotein E (ApoE) epsilon 4 allele confers significant risk for Alzheimer's disease and is associated with a greater amyloid burden in the brain. Future treatments may target molecular mechanisms associated with this allele, and it is important to define any phenotypic characteristics that correspond to this genotype. We sought to clarify the relationship between ApoE status and noncognitive symptoms in Alzheimer's disease patients.
Possible and probable Alzheimer's disease patients from a clinical trial (n = 605) were assessed with the 10-item Neuropsychiatric Inventory cross-sectionally prior to treatment, and their ApoE genotype was determined. Among the population studied, the following numbers with specific genotypes were studied: 23-2/3, 17-2/4, 209-3/3, 288-3/4, 68-4/4.
When correlations were controlled for the patient's level of cognitive impairment, there was no relationship between epsilon 4 dose and any of the 10 noncognitive symptoms assessed, including psychosis, mood changes, and personality alterations.
Among patients with comparable disease severity, the epsilon 4 allele does not confer additional psychiatric morbidity.
载脂蛋白E（ApoE）ε4等位基因赋予患阿尔茨海默病的显著风险，并与大脑中更高的淀粉样蛋白负担相关。未来的治疗可能针对与该等位基因相关的分子机制，明确任何与该基因型相对应的表型特征很重要。我们试图阐明阿尔茨海默病患者中ApoE状态与非认知症状之间的关系。
来自一项临床试验的可能及很可能患阿尔茨海默病的患者（n = 605）在治疗前接受了10项神经精神科问卷的横断面评估，并确定了他们的ApoE基因型。在所研究的人群中，对具有特定基因型的以下人数进行了研究：23例-2/3、17例-2/4、209例-3/3、288例-3/4、68例-4/4。
当对患者的认知障碍水平进行相关性控制时，ε4剂量与所评估的10种非认知症状中的任何一种之间均无关联，这些症状包括精神病、情绪变化和人格改变。
在疾病严重程度相当的患者中，ε4等位基因不会导致额外的精神疾病发病率。
